ProCE Banner Activity

BRCAAway: Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in HRR-Mutant Metastatic CRPC

Conference Coverage
Slideset

Analysis from the phase II BRCAAway trial found that olaparib plus abiraterone/prednisone resulted in longer PFS and higher ORR vs olaparib or abiraterone/prednisone monotherapy in patients with mCRPC and BRCA1/2 or ATM mutations.

Released: January 30, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

AstraZeneca

Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC